Cynata Therapeutics Ltd (ASX:CYP "Cynata") has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19.
What are the key highlights?
- Compromised lung function, which can ultimately progress to acute respiratory distress syndrome (ARDS), is a major complication in COVID-19 patients.
- This trial will build on Cynata’s strong pre-clinical study results in ARDS, sepsis and cytokine release syndrome, all of which are common hallmarks of severe COVID-19 cases.
- The MEND trial is an open-label, randomised controlled clinical trial to investigate early efficacy of Cymerus MSCs.
- The MEND Trial is to be conducted at centres in New South Wales in collaboration with the Cerebral Palsy Alliance Research Institute and investigators from the COVID-19 Stem Cell Treatment (CSCT) Group.